Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heparin-induced thrombocytopenia].

K Gürtler1, I Euchner-Wamser, G Neeser

  • 1Klinik für Anästhesiologie und Operative Intensivmedizin, Klinikum Augsburg, 86156 , Augsburg, Germany. karlheinz.guertler@klinikum-augsburg.de

Der Anaesthesist
|September 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[82 years old, male high-risk cardiac patient to planned Y-prosthesis implantation for abdominal aortic aneurysm : Preparation for the medical specialist examination: part 38].

Der Anaesthesist·2019
Same author

[70-year-old male with more than 40 pack years scheduled for implant removal : Preparation for the medical specialist examination: Part 1].

Der Anaesthesist·2019
Same author

[New oral anticoagulants in perioperative medicine].

Der Anaesthesist·2014
Same author

[Awake fiberoptic intubation].

Der Anaesthesist·2011
Same author

[Organ donation].

Der Anaesthesist·2007
Same author

Correlation of MMSE, SKT and clock test scores in patients with mild and moderate dementia.

Nagoya journal of medical science·2007
Same journal

[Promoting young academics in anesthesiology: factors for an attractive internship].

Der Anaesthesist·2022
Same journal

[Respiratory support in COVID-19: all in due time!]

Der Anaesthesist·2022
Same journal

[Noninvasive respiratory support and invasive ventilation in COVID‑19 : Where do we stand today?]

Der Anaesthesist·2022
Same journal

[Management of acutely decompensated liver cirrhosis in emergency and critical care medicine].

Der Anaesthesist·2022
Same journal

[Anesthesia in patients with acute porphyria].

Der Anaesthesist·2022
Same journal

[Quality and safe anesthesia for all children : That is their right!]

Der Anaesthesist·2022
See all related articles

Heparin-induced thrombocytopenia type II (HIT type II) is a dangerous immune side effect of anticoagulant therapy, causing dangerous blood clots. Diagnosis and management are critical, especially in surgery patients.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Heparins are widely used anticoagulants for preventing and treating thromboembolisms.
  • A serious adverse effect is heparin-induced thrombocytopenia type II (HIT type II), an immune condition causing paradoxical thromboembolic occlusions.
  • HIT type II involves platelet activation and plasma coagulation, leading to acute thrombocytopenia.

Purpose of the Study:

  • To review the diagnosis and differential diagnosis of HIT type II.
  • To emphasize diagnostic challenges in postoperative intensive care patients.
  • To discuss preventive measures and management strategies for HIT type II and associated thrombotic complications.

Main Methods:

  • Literature review of heparin-induced thrombocytopenia type II.

Related Experiment Videos

  • Analysis of diagnostic criteria and differential diagnoses.
  • Discussion of clinical management and prevention strategies.

    • Main Results:

    • HIT type II presents as acute thrombocytopenia (platelet count <50% of baseline) 5-14 days after heparin initiation.
    • Thromboembolic complications (venous and arterial) are common.
    • Postoperative patients exhibit higher rates of subclinical antibody formation and symptomatic HIT type II.

    Conclusions:

    • Accurate and timely diagnosis of HIT type II is challenging, particularly in intensive care settings.
    • Early recognition and appropriate management are crucial to prevent severe thrombotic events.
    • Preventive strategies and alternative anticoagulation are essential for at-risk patients.